Amylyx eyes FDA filing for GLP-1 blocker after late-stage win in post-bariatric hypoglycemia

Phase 3positiveavexitidePositive

AI Analysis

Summary

Amylyx Pharmaceuticals achieved positive Phase 3 results for avexitide in post-bariatric hypoglycemia, with plans to file for FDA approval in 2026. Analysts estimate peak worldwide sales of $1.7 billion if approved.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Phase 3 trial reducing serious and severe hypoglycemic episodes following weight loss surgery

Importance:7/10

Sentiment:

0.75

Phase 3 positiveFDA filing plannedGLP-1 blockerpost-bariatric hypoglycemiapeak sales estimate

Related Companies

$AMLX

Read the original article

Published by BioSpace on August 18, 2026 11:01 AM

Read Original